2016
The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy
Mallick A, Gandhi PU, Gaggin HK, Ibrahim N, Januzzi JL. The Importance of Worsening Heart Failure in Ambulatory Patients Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. JACC Heart Failure 2016, 4: 749-755. PMID: 27179830, DOI: 10.1016/j.jchf.2016.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenergic beta-AntagonistsAgedAmbulatory CareAngiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesDisease ProgressionFemaleHeart FailureHospitalizationHumansMaleMiddle AgedMineralocorticoid Receptor AntagonistsNatriuretic Peptide, BrainPatient Care PlanningPeptide FragmentsProportional Hazards ModelsSodium Potassium Chloride Symporter InhibitorsStandard of CareTreatment OutcomeConceptsHeart failureChronic HFrEFNT-proBNPEjection fractionN-terminal pro-B-type natriuretic peptide concentrationsHigher loop diuretic dosesAngiotensin-converting enzyme inhibitorB-type natriuretic peptideAmbulatory heart failureAmino-Terminal ProJugular venous distensionLoop diuretic dosesAcute heart failureDecompensated heart failureReduced ejection fractionEvent-free survivalNatriuretic peptide concentrationsHigher ejection fractionStandard of careRelevant clinical eventsDiuretic therapyHF managementCardiovascular deathDiuretic dosesVenous distension
2015
Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure
Gandhi P, Januzzi Jr. J. Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. Biomarkers In Disease: Methods, Discoveries And Applications 2015, 731-756. DOI: 10.1007/978-94-007-7696-8_12.ChaptersB-type natriuretic peptideHeart failureNatriuretic peptideEjection fractionAmino-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHeart failure screeningReduced ejection fractionNatriuretic peptide releaseUse of biomarkersComplicated patientsRoutine carePressure overloadClinical assessmentMyocyte stretchCardiovascular homeostasisFluid balanceCardiac conditionsComplex syndromePatientsPersonalized carePeptide releaseMultiple studiesMillions of peopleCareGalectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction
Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Rocca H, Januzzi JL. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal 2015, 169: 404-411.e3. PMID: 25728731, DOI: 10.1016/j.ahj.2014.12.012.Peer-Reviewed Original ResearchConceptsElevated galectin-3Mineralocorticoid receptor antagonistsCV event ratesMRA therapyGalectin-3 concentrationsQuality of lifeGalectin-3CV eventsHeart failureMRA useLeft ventricular systolic dysfunctionMineralocorticoid receptor antagonist useTreatment-related adverse eventsEvent ratesBaseline galectin-3Ventricular remodeling indexChronic heart failureOutcomes of patientsReduced ejection fractionVentricular systolic dysfunctionReceptor antagonist useSignificant renal dysfunctionFirst CV eventHeart failure biomarkersChronic HFrEF
2014
Prognostic Usefulness of Insulin-Like Growth Factor-Binding Protein 7 in Heart Failure With Reduced Ejection Fraction: A Novel Biomarker of Myocardial Diastolic Function?
Gandhi PU, Gaggin HK, Sheftel AD, Belcher AM, Weiner RB, Baggish AL, Motiwala SR, Liu PP, Januzzi JL. Prognostic Usefulness of Insulin-Like Growth Factor-Binding Protein 7 in Heart Failure With Reduced Ejection Fraction: A Novel Biomarker of Myocardial Diastolic Function? The American Journal Of Cardiology 2014, 114: 1543-1549. PMID: 25248814, DOI: 10.1016/j.amjcard.2014.08.018.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersDisease ProgressionEchocardiography, DopplerFemaleFollow-Up StudiesHeart Failure, DiastolicHumansInsulin-Like Growth Factor Binding ProteinsMaleMiddle AgedMyocardial ContractionPrognosisProspective StudiesSeverity of Illness IndexStroke VolumeTime FactorsVentricular Function, LeftConceptsInsulin-like growth factor-binding protein 7Right ventricular systolic pressureReduced ejection fractionAtrial volume indexVentricular systolic pressureTransmitral E/Diastolic functionIGFBP7 concentrationsHeart failureEjection fractionSystolic pressureVolume indexEchocardiographic parametersHigher left atrial volume indexLeft atrial volume indexInsulin-like growth factorAmbulatory heart failureAbnormal diastolic functionMyocardial diastolic functionNovel prognostic biomarkerProtein 7Binding protein 7Echocardiographic abnormalitiesFinal echocardiogramCardiovascular eventsNatriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure
Gandhi P, Januzzi Jr. J. Natriuretic Peptides for Diagnosis, Prognosis, and Management of Heart Failure. 2014, 1-21. DOI: 10.1007/978-94-007-7740-8_12-1.ChaptersB-type natriuretic peptideHeart failureNatriuretic peptideEjection fractionAmino-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHeart failure screeningReduced ejection fractionNatriuretic peptide releaseUse of biomarkersComplicated patientsRoutine carePressure overloadClinical assessmentMyocyte stretchCardiovascular homeostasisFluid balanceCardiac conditionsComplex syndromePatientsPersonalized carePeptide releaseMultiple studiesMillions of peopleCare